100
Participants
Start Date
January 31, 2016
Primary Completion Date
November 30, 2019
Study Completion Date
August 31, 2021
Molecular guided therapy
Biomarker-driven therapy according to recommandations of the precision oncology tumor board including MEK Inhibitors (Trametinib 2 mg/d, Selumetinib 75 mg 2/d), MET Inhibitors (Crizotinib 250 mg 2/d, or Cabozantinib 60mg/d), RAS Inhibitor (Sorafenib 400 mg 2/d), Cell cycle Inhibitor (Palbociclib 125 mg/d) and Checkpoint Inhibitor (Nivolumab 240 mg every 2 weeks).
Collaborators (1)
Max-Planck Institut
UNKNOWN
Alacris
UNKNOWN
Charite University, Berlin, Germany
OTHER